1-3 of 3
Jennifer L. Schutzman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors

Yoonha Choi, Neekesh V. Dharia, Tomi Jun, Julie Chang, Stephanie Royer-Joo, Kenneth K. Yau, Zoe J. Assaf, Junko Aimi, Smruthy Sivakumar, Meagan Montesion, Adrian Sacher, Patricia LoRusso, Jayesh Desai, Jennifer L. Schutzman, Zhen Shi, and the GO42144 study group
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (17): 3788–3797.
https://doi.org/10.1158/1078-0432.CCR-24-0255
Published: 03 September 2024
View article titled, Circulating Tumor DNA Dynamics Reveal <em>KRAS G12C</em> Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors
Open the PDF for Circulating Tumor DNA Dynamics Reveal <em>KRAS G12C</em> Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract 29: Utility of novel clinico-genomic data to understand patient characteristics, treatments, and outcomes according to PIK3CA mutation status among hormone receptor-positive metastatic breast cancer patients

Mary K. Downer, Peter Lambert, Sami Mahrus, Katherine E. Hutchinson, Patricia Luhn, Jennifer L. Schutzman
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (12_Supplement_1): 29.
https://doi.org/10.1158/1557-3265.ADVPRECMED20-29
Published: 15 June 2020
View article titled, Abstract 29: Utility of novel clinico-genomic data to understand patient characteristics, treatments, and outcomes according to <em>PIK3CA</em> mutation status among hormone receptor-positive metastatic breast cancer patients
Journal Articles

Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors

Jeffrey R. Infante, Antoine Hollebecque, Sophie Postel-Vinay, Todd M. Bauer, Elizabeth M. Blackwood, Marie Evangelista, Sami Mahrus, Franklin V. Peale, Xuyang Lu, Srikumar Sahasranaman, Rui Zhu, Yuan Chen, Xiao Ding, Elaine R. Murray, Jennifer L. Schutzman, Jennifer O. Lauchle, Jean-Charles Soria, Patricia M. LoRusso
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (10): 2423–2432.
https://doi.org/10.1158/1078-0432.CCR-16-1782
Published: 14 May 2017
View article titled, Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
Open the PDF for Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors in another window
Includes: Supplementary data